董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Madhavan Balachandran | 男 | Director | 70 | 未披露 | 未持股 | 2021-07-15 |
| Franco Stevanato | 男 | Director-Executive Chairman | 47 | 未披露 | 未持股 | 2021-07-15 |
| Marco Stevanato | 男 | Director-Vice-Chairman | 48 | 未披露 | 未持股 | 2021-07-15 |
| Fabiano Nicoletti | 男 | Director | 77 | 未披露 | 未持股 | 2021-07-15 |
| Alvise Spinazzi | 男 | Director | 48 | 未披露 | 未持股 | 2021-07-15 |
| Fabio Buttignon | 男 | Director | 61 | 未披露 | 未持股 | 2021-07-15 |
| Donald Eugene Morel Jr. | 男 | Director | 63 | 未披露 | 未持股 | 2021-07-15 |
| William Federici | 男 | Director | 62 | 未披露 | 未持股 | 2021-07-15 |
| Paola Vezzaro | 女 | Director | 53 | 未披露 | 未持股 | 2021-07-15 |
| Franco Moro | 男 | Director, Chief Executive Officer and Chief Operating Officer | 58 | 未披露 | 未持股 | 2021-07-15 |
| Fabrizio Bonanni | 男 | Director | 74 | 未披露 | 未持股 | 2021-07-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Franco Moro | 男 | Director, Chief Executive Officer and Chief Operating Officer | 58 | 未披露 | 未持股 | 2021-07-15 |
| Marco Dal Lago | 男 | Chief Financial Officer | 49 | 未披露 | 未持股 | 2021-07-15 |
| Mauro Stocchi | 男 | Chief Business Officer | 55 | 未披露 | 未持股 | 2021-07-15 |
| Paolo Patri | 男 | Chief Technology Officer | 51 | 未披露 | 未持股 | 2021-07-15 |
董事简历
中英对照 | 中文 | 英文- Madhavan Balachandran
-
Madhavan Balachandran自2017年9月起担任Catalent, Inc.董事会成员。Balachandran先生自2017年5月起担任Catalent纽约证券交易所代码：CTLT的董事。Balachandran先生于2012年8月至2016年7月担任全球生物技术公司安进公司运营执行副总裁，并于2017年1月以执行副总裁的身份退休。Balachandran先生于1997年加入Amgen，担任工程副总监。他于1998年成为工程总监，并于1999年至2001年担任工程和运营服务高级总监，然后于2001年至2002年担任信息系统副总裁。此后，Balachandran先生于2002年5月至2007年2月担任波多黎各业务副总裁。2007年2月至2007年10月，Balachandran先生担任现场运营副总裁，2007年10月至2012年8月，他担任制造高级副总裁。在安进任职之前，Balachandran先生曾在Copley Pharmaceuticals（现为Teva Pharmaceuticals Industries Ltd.的一部分）和Burroughs Wellcome Company（GlaxoSmithKline plc合并前的前身）担任领导职务。Balachandran先生拥有纽约州立大学布法罗分校的化学工程理学硕士学位和东卡罗来纳大学的MBA学位。
Madhavan Balachandran,was Chief Operating Officer of Nutcracker Therapeutics, a developer of mRNA therapeutics, from September 2020 to March 2022. Mr. Balachandran was Executive Vice President, Operations of Amgen Inc., a global biotechnology company, from August 2012 until July 2016 and retired as an Executive Vice President in January 2017. Mr. Balachandran joined Amgen in 1997 as Associate Director, Engineering. He became Director, Engineering in 1998, and, from 1999 to 2001, he held the position of Senior Director, Engineering and Operations Services before moving to the position of Vice President, Information Systems from 2001 to 2002. Thereafter, Mr. Balachandran was Vice President, Puerto Rico Operations from May 2002 to February 2007. From February 2007 to October 2007, Mr. Balachandran was Vice President, Site Operations, and from October 2007 to August 2012, he held the position of Senior Vice President, Manufacturing. Prior to his tenure at Amgen, Mr. Balachandran held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd., and Burroughs Wellcome Company, a predecessor before mergers of GlaxoSmithKline plc. He currently serves on the board of directors of A2 Biotherapeutics, Inc. Stevanato Group (NYSE: STVN), and Replimune Group, Inc. (Nasdaq: REPL). Mr. Balachandran previously served as a director of Catalent, Inc. (NYSE: CTLT) from May 2017 to January 2024. Mr. Balachandran holds a Master of Science degree in Chemical Engineering from The State University of New York at Buffalo, a Bachelor's degree in Chemical Engineering from the Indian Institute of Technology, Bombay, and an MBA from East Carolina University. - Madhavan Balachandran自2017年9月起担任Catalent, Inc.董事会成员。Balachandran先生自2017年5月起担任Catalent纽约证券交易所代码：CTLT的董事。Balachandran先生于2012年8月至2016年7月担任全球生物技术公司安进公司运营执行副总裁，并于2017年1月以执行副总裁的身份退休。Balachandran先生于1997年加入Amgen，担任工程副总监。他于1998年成为工程总监，并于1999年至2001年担任工程和运营服务高级总监，然后于2001年至2002年担任信息系统副总裁。此后，Balachandran先生于2002年5月至2007年2月担任波多黎各业务副总裁。2007年2月至2007年10月，Balachandran先生担任现场运营副总裁，2007年10月至2012年8月，他担任制造高级副总裁。在安进任职之前，Balachandran先生曾在Copley Pharmaceuticals（现为Teva Pharmaceuticals Industries Ltd.的一部分）和Burroughs Wellcome Company（GlaxoSmithKline plc合并前的前身）担任领导职务。Balachandran先生拥有纽约州立大学布法罗分校的化学工程理学硕士学位和东卡罗来纳大学的MBA学位。
- Madhavan Balachandran,was Chief Operating Officer of Nutcracker Therapeutics, a developer of mRNA therapeutics, from September 2020 to March 2022. Mr. Balachandran was Executive Vice President, Operations of Amgen Inc., a global biotechnology company, from August 2012 until July 2016 and retired as an Executive Vice President in January 2017. Mr. Balachandran joined Amgen in 1997 as Associate Director, Engineering. He became Director, Engineering in 1998, and, from 1999 to 2001, he held the position of Senior Director, Engineering and Operations Services before moving to the position of Vice President, Information Systems from 2001 to 2002. Thereafter, Mr. Balachandran was Vice President, Puerto Rico Operations from May 2002 to February 2007. From February 2007 to October 2007, Mr. Balachandran was Vice President, Site Operations, and from October 2007 to August 2012, he held the position of Senior Vice President, Manufacturing. Prior to his tenure at Amgen, Mr. Balachandran held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd., and Burroughs Wellcome Company, a predecessor before mergers of GlaxoSmithKline plc. He currently serves on the board of directors of A2 Biotherapeutics, Inc. Stevanato Group (NYSE: STVN), and Replimune Group, Inc. (Nasdaq: REPL). Mr. Balachandran previously served as a director of Catalent, Inc. (NYSE: CTLT) from May 2017 to January 2024. Mr. Balachandran holds a Master of Science degree in Chemical Engineering from The State University of New York at Buffalo, a Bachelor's degree in Chemical Engineering from the Indian Institute of Technology, Bombay, and an MBA from East Carolina University.
- Franco Stevanato
-
Franco Stevanato，Sergio Stevanato之子，Franco Stevanato，1998年毕业于的里雅斯特大学政治学，2015年进入凯洛格管理学院（Kellogg School of Management）高级管理课程。大学期间，他在法国圣戈班（Saint Gobain）销售部获得了专业经验。完成学业后，他加入了家族企业，最初在销售部门工作。多年来，他一直是公司国际化及其从产品多样化（通过战略收购和内部创新）到强化管理流程和结构改进的持续发展背后的关键人物和驱动力。他还为改善Stevanato集团的公司治理做出了贡献，建立了有效的基础设施来支持决策，并促进了一个基于技能的董事会，该董事会受益于专业知识和有意义的视角。他从2010年到2020年一直担任该集团的首席执行官。从2021年起，他担任董事会执行主席。
Franco Stevanato,Son of Sergio Stevanato, Franco Stevanato graduated in Political Science from the University of Trieste in 1998 and attended an Advanced Management Program at the Kellogg School of Management in 2015. During his university years, he gained professional experience in the sales department of Saint Gobain in France. Upon completing his studies, he joined the family business, initially taking up a role in sales. Over the years, he has been the key figure and driving force behind the internationalization of the Company and its continuing development from product diversification - via strategic acquisitions and in house innovations - to enhanced managerial processes and structural improvements. He also contributed to improving the Stevanato Group’s corporate governance by building an effective infrastructure to support decision making and promoting a skills-based board that benefits from specialist expertise and meaningful perspective. He has been CEO of the Group from 2010 to 2020. From 2021 he is the Executive Chairman of the Board. - Franco Stevanato，Sergio Stevanato之子，Franco Stevanato，1998年毕业于的里雅斯特大学政治学，2015年进入凯洛格管理学院（Kellogg School of Management）高级管理课程。大学期间，他在法国圣戈班（Saint Gobain）销售部获得了专业经验。完成学业后，他加入了家族企业，最初在销售部门工作。多年来，他一直是公司国际化及其从产品多样化（通过战略收购和内部创新）到强化管理流程和结构改进的持续发展背后的关键人物和驱动力。他还为改善Stevanato集团的公司治理做出了贡献，建立了有效的基础设施来支持决策，并促进了一个基于技能的董事会，该董事会受益于专业知识和有意义的视角。他从2010年到2020年一直担任该集团的首席执行官。从2021年起，他担任董事会执行主席。
- Franco Stevanato,Son of Sergio Stevanato, Franco Stevanato graduated in Political Science from the University of Trieste in 1998 and attended an Advanced Management Program at the Kellogg School of Management in 2015. During his university years, he gained professional experience in the sales department of Saint Gobain in France. Upon completing his studies, he joined the family business, initially taking up a role in sales. Over the years, he has been the key figure and driving force behind the internationalization of the Company and its continuing development from product diversification - via strategic acquisitions and in house innovations - to enhanced managerial processes and structural improvements. He also contributed to improving the Stevanato Group’s corporate governance by building an effective infrastructure to support decision making and promoting a skills-based board that benefits from specialist expertise and meaningful perspective. He has been CEO of the Group from 2010 to 2020. From 2021 he is the Executive Chairman of the Board.
- Marco Stevanato
-
Marco Stevanato，Sergio Stevanato之子，1998年毕业于的里雅斯特大学工商管理专业。毕业后，他在德国、比利时和美国获得了一家德国跨国公司的财务和控制部门的经验，然后于1999年加入家族企业。2006年，他被任命为Stevanato Group的副总裁，并领导位于墨西哥蒙特雷、中国张家港和巴西Sete Lagoas的工厂的国际化项目和开发。他还担任SFEM Italia S.R.L.（家族办公室，管理Stevanato家族的投资，与工业集团无关）的首席执行官。
Marco Stevanato,Son of Sergio Stevanato, Marco Stevanato graduated in Business Administration from the University of Trieste in 1998. After graduation, he gained experience in Germany, Belgium and the United States in the Finance & Controlling department of a German multinational company to then join the family business in 1999. In 2006 he was appointed Vice President of the Stevanato Group and has led the internationalization projects and development of the plants in Monterrey Mexico, Zhangjiagang (China) and Sete Lagoas (Brazil). He also serves as Chief Executive Officer of SFEM ITALIA S.r.l., the Family Office that manages the investments of the Stevanato family, not related to the industrial group. - Marco Stevanato，Sergio Stevanato之子，1998年毕业于的里雅斯特大学工商管理专业。毕业后，他在德国、比利时和美国获得了一家德国跨国公司的财务和控制部门的经验，然后于1999年加入家族企业。2006年，他被任命为Stevanato Group的副总裁，并领导位于墨西哥蒙特雷、中国张家港和巴西Sete Lagoas的工厂的国际化项目和开发。他还担任SFEM Italia S.R.L.（家族办公室，管理Stevanato家族的投资，与工业集团无关）的首席执行官。
- Marco Stevanato,Son of Sergio Stevanato, Marco Stevanato graduated in Business Administration from the University of Trieste in 1998. After graduation, he gained experience in Germany, Belgium and the United States in the Finance & Controlling department of a German multinational company to then join the family business in 1999. In 2006 he was appointed Vice President of the Stevanato Group and has led the internationalization projects and development of the plants in Monterrey Mexico, Zhangjiagang (China) and Sete Lagoas (Brazil). He also serves as Chief Executive Officer of SFEM ITALIA S.r.l., the Family Office that manages the investments of the Stevanato family, not related to the industrial group.
- Fabiano Nicoletti
-
Fabiano Nicoletti，1943年出生于威尼斯，1972年毕业于帕多瓦大学，主修固体物理学。他在威尼斯的意大利国家玻璃研究所（Stazione Sperimentale del Vetro）获得了40多年的工作经验。长期以来，他在多个国际委员会和工作小组中开展合作，他是欧洲玻璃科学与技术协会（ESG）的创始人之一（和主席），他是该协会的名誉主席，是欧洲科学与技术联盟（USTV）的主席，以及ICG（国际玻璃委员会）主席。1983年和1993年，意大利共和国总统分别授予卡瓦利埃·奥尔丁·梅里托·德拉共和国总统和梅里托·德拉共和国总统荣誉勋章。自2003年以来，他一直是Stevanato Group的董事会成员。
Fabiano Nicoletti,Born in Venice in 1943 Fabiano Nicoletti graduated in Solid State Physics from the University of Padua in 1972. He gained more than forty years of experience at Stazione Sperimentale del Vetro the Italian State Glass Research Institute in Venice. For a long time, he collaborated in several international committees and working groups and he was one of the founders (and President) of the European Society of Glass Science and Technology (ESG) of which he is Honorary President, the President of USTV (Union Scientifique et Technologique du Verre), as well as the President of the ICG (International Commission on Glass). Both in 1983 and 1993 he was awarded by the President of the Italian Republic the honorary recognitions of “Cavaliere Ordine al Merito della Repubblica” and of “Ufficiale Ordine al Merito della Repubblica”, respectively. He has been a member of the board of directors of Stevanato Group since 2003. - Fabiano Nicoletti，1943年出生于威尼斯，1972年毕业于帕多瓦大学，主修固体物理学。他在威尼斯的意大利国家玻璃研究所（Stazione Sperimentale del Vetro）获得了40多年的工作经验。长期以来，他在多个国际委员会和工作小组中开展合作，他是欧洲玻璃科学与技术协会（ESG）的创始人之一（和主席），他是该协会的名誉主席，是欧洲科学与技术联盟（USTV）的主席，以及ICG（国际玻璃委员会）主席。1983年和1993年，意大利共和国总统分别授予卡瓦利埃·奥尔丁·梅里托·德拉共和国总统和梅里托·德拉共和国总统荣誉勋章。自2003年以来，他一直是Stevanato Group的董事会成员。
- Fabiano Nicoletti,Born in Venice in 1943 Fabiano Nicoletti graduated in Solid State Physics from the University of Padua in 1972. He gained more than forty years of experience at Stazione Sperimentale del Vetro the Italian State Glass Research Institute in Venice. For a long time, he collaborated in several international committees and working groups and he was one of the founders (and President) of the European Society of Glass Science and Technology (ESG) of which he is Honorary President, the President of USTV (Union Scientifique et Technologique du Verre), as well as the President of the ICG (International Commission on Glass). Both in 1983 and 1993 he was awarded by the President of the Italian Republic the honorary recognitions of “Cavaliere Ordine al Merito della Repubblica” and of “Ufficiale Ordine al Merito della Repubblica”, respectively. He has been a member of the board of directors of Stevanato Group since 2003.
- Alvise Spinazzi
-
Alvise Spinazzi，1997年毕业于帕多瓦大学法律系，获法学硕士学位。纽约福德姆大学法学院国际商业和贸易法律专业。他于2000年在纽约和2001年在意大利获得律师资格。在2007年与其他合伙人在帕多瓦成立律师事务所Sat Studio Legale之前，他在国际律师事务所Simpson Thacher&Bartlett的纽约办事处和意大利律师事务所Chiomenti的米兰办事处执业。自2011年以来，他一直是Stevanato Group的董事会成员。
Alvise Spinazzi,Graduated in Law from the University of Padua in 1997 he obtained an LL.M. in International Business and Trade Law from Fordham University School of Law in New York. He qualified as a lawyer in New York in 2000 and in Italy in 2001. Before founding with other partners the law firm SAT Studio Legale in Padua in 2007 he practiced in the New York office of the international law firm Simpson Thacher & Bartlett and in the Milan office of Italian law firm Chiomenti. He has been a member of the board of directors of Stevanato Group since 2011. - Alvise Spinazzi，1997年毕业于帕多瓦大学法律系，获法学硕士学位。纽约福德姆大学法学院国际商业和贸易法律专业。他于2000年在纽约和2001年在意大利获得律师资格。在2007年与其他合伙人在帕多瓦成立律师事务所Sat Studio Legale之前，他在国际律师事务所Simpson Thacher&Bartlett的纽约办事处和意大利律师事务所Chiomenti的米兰办事处执业。自2011年以来，他一直是Stevanato Group的董事会成员。
- Alvise Spinazzi,Graduated in Law from the University of Padua in 1997 he obtained an LL.M. in International Business and Trade Law from Fordham University School of Law in New York. He qualified as a lawyer in New York in 2000 and in Italy in 2001. Before founding with other partners the law firm SAT Studio Legale in Padua in 2007 he practiced in the New York office of the international law firm Simpson Thacher & Bartlett and in the Milan office of Italian law firm Chiomenti. He has been a member of the board of directors of Stevanato Group since 2011.
- Fabio Buttignon
-
Fabio Buttignon，1983年毕业于威尼斯福斯卡利大学经济学和工商管理专业。他在加州大学洛杉矶分校（University of California，Los Angeles）从事金融和战略方面的研究活动。他是威尼斯福斯卡利大学（University CA’；Fosari of Venice）的研究员、助理教授和企业管理副教授。Buttignon先生目前是帕多瓦大学经济与管理系的企业金融学教授。他是Buttignon Zotti Milan&Co.（一家专注于企业财务和会计服务的金融咨询精品公司）的创始人和管理合伙人，拥有Dottore Commercialista和Reviore Dei Conti注册会计师和法定审计师的资格。自2014年以来，他一直是Stevanato Group的董事会成员。
Fabio Buttignon,Graduated in Economics and Business Administration from the University Ca’ Foscari of Venice in 1983. He carried out research activities in Finance and Strategy at the University of California, Los Angeles. He was research fellow, assistant professor and associate professor of Business Administration at the University Ca’ Foscari of Venice. Mr. Buttignon is currently full professor of Corporate Finance at the University of Padua, Department of Economics and Management. Qualified as Dottore Commercialista and Revisore dei Conti CPA and Statutory Auditor, he is founder and managing partner of Buttignon Zotti Milan & Co., a financial advisory boutique specialized in corporate finance and accounting services. He has been a member of the board of directors of Stevanato Group since 2014. - Fabio Buttignon，1983年毕业于威尼斯福斯卡利大学经济学和工商管理专业。他在加州大学洛杉矶分校（University of California，Los Angeles）从事金融和战略方面的研究活动。他是威尼斯福斯卡利大学（University CA’；Fosari of Venice）的研究员、助理教授和企业管理副教授。Buttignon先生目前是帕多瓦大学经济与管理系的企业金融学教授。他是Buttignon Zotti Milan&Co.（一家专注于企业财务和会计服务的金融咨询精品公司）的创始人和管理合伙人，拥有Dottore Commercialista和Reviore Dei Conti注册会计师和法定审计师的资格。自2014年以来，他一直是Stevanato Group的董事会成员。
- Fabio Buttignon,Graduated in Economics and Business Administration from the University Ca’ Foscari of Venice in 1983. He carried out research activities in Finance and Strategy at the University of California, Los Angeles. He was research fellow, assistant professor and associate professor of Business Administration at the University Ca’ Foscari of Venice. Mr. Buttignon is currently full professor of Corporate Finance at the University of Padua, Department of Economics and Management. Qualified as Dottore Commercialista and Revisore dei Conti CPA and Statutory Auditor, he is founder and managing partner of Buttignon Zotti Milan & Co., a financial advisory boutique specialized in corporate finance and accounting services. He has been a member of the board of directors of Stevanato Group since 2014.
- Donald Eugene Morel Jr.
-
Donald Eugene Morel Jr.博士拥有拉斐特大学中国中冶工程学士学位、康奈尔大学材料科学硕士学位和兽医博士学位，还完成了弗吉尼亚大学达顿商学院的执行项目。在获得专注于先进卫星系统的广泛的空间相关研究项目的经验后，Morel先生加入了West PharmaceuticalServices，Inc.，在那里他从2003年4月开始担任董事长，从2002年4月开始担任首席执行官，直到2015年6月退休。Morel博士撰写或合著了30多种科学出版物，并当选为美国医学和生物工程研究所研究员。他目前担任Catalent Inc.和Integra Life Sciences Holdings的董事会成员。自2018年以来，他一直是Stevanato Group的董事会成员。
Donald Eugene Morel Jr.,Holding BS degree in Metallurgical Engineering from Lafayette, an MS in Materials Science and a Ph.D. in Materials Science and Veterinary Medicine from Cornell University, Dr. Morel also completed the Executive Program at Darden School of Business-University of Virginia. After gaining experience in a broad range of space related research programs focused on advanced satellite systems, Mr. Morel joined West Pharmaceutical Services, Inc., where he served as Chairman from April 2003 and Chief Executive Officer from April 2002 until his retirement in June of 2015. Dr. Morel has authored or co-authored over thirty scientific publications and was elected a fellow of the American Institute for Medical & Biologic Engineering. he currently serves as a member of the board of directors in Catalent Inc. and Integra Life Sciences Holdings. He has been a member of the board of directors of Stevanato Group since 2018. - Donald Eugene Morel Jr.博士拥有拉斐特大学中国中冶工程学士学位、康奈尔大学材料科学硕士学位和兽医博士学位，还完成了弗吉尼亚大学达顿商学院的执行项目。在获得专注于先进卫星系统的广泛的空间相关研究项目的经验后，Morel先生加入了West PharmaceuticalServices，Inc.，在那里他从2003年4月开始担任董事长，从2002年4月开始担任首席执行官，直到2015年6月退休。Morel博士撰写或合著了30多种科学出版物，并当选为美国医学和生物工程研究所研究员。他目前担任Catalent Inc.和Integra Life Sciences Holdings的董事会成员。自2018年以来，他一直是Stevanato Group的董事会成员。
- Donald Eugene Morel Jr.,Holding BS degree in Metallurgical Engineering from Lafayette, an MS in Materials Science and a Ph.D. in Materials Science and Veterinary Medicine from Cornell University, Dr. Morel also completed the Executive Program at Darden School of Business-University of Virginia. After gaining experience in a broad range of space related research programs focused on advanced satellite systems, Mr. Morel joined West Pharmaceutical Services, Inc., where he served as Chairman from April 2003 and Chief Executive Officer from April 2002 until his retirement in June of 2015. Dr. Morel has authored or co-authored over thirty scientific publications and was elected a fellow of the American Institute for Medical & Biologic Engineering. he currently serves as a member of the board of directors in Catalent Inc. and Integra Life Sciences Holdings. He has been a member of the board of directors of Stevanato Group since 2018.
- William Federici
-
William Federici拥有罗格斯大学、利文斯顿学院的经济学学士学位和罗格斯大学的专业会计MBA学位，他是美国注册会计师协会的成员。Federici先生一直担任Zynerba制药公司（一家专业制药公司，美国上市公司）的董事会成员，在那里他自2015年以来担任审计委员会主席。Federici先生于2003年加入West PharmaceuticalServices，Inc.（一家纽交所上市的美国上市公司），担任首席财务官，此前在公共会计领域有超过20年的经验，主要服务于制药行业。他于2018年从West PharmaceuticalServices，Inc.退休。他已于2021年5月被任命为Stevanato Group的董事会成员。
William Federici,Holding a BA in Economics from Rutgers University, Livingston College and an MBA in Professional Accounting from Rutgers University, he is a member of the American Institute of Certified Public Accountants. Mr. Federici has been a member of the board of directors of Zynerba Pharmaceuticals, Inc., a Specialty Pharmaceutical, U.S. public company, where he has served as Audit Committee Board Chair since 2015. Mr. Federici joined West Pharmaceutical Services, Inc., a NYSE traded U.S. public company, in 2003 as Chief Financial Officer after more than 20 years’ experience in public accounting primarily serving the Pharmaceutical Industry. He retired from West Pharmaceutical Services, Inc. in 2018. He has been appointed as member of the board of directors of Stevanato Group in May 2021. - William Federici拥有罗格斯大学、利文斯顿学院的经济学学士学位和罗格斯大学的专业会计MBA学位，他是美国注册会计师协会的成员。Federici先生一直担任Zynerba制药公司（一家专业制药公司，美国上市公司）的董事会成员，在那里他自2015年以来担任审计委员会主席。Federici先生于2003年加入West PharmaceuticalServices，Inc.（一家纽交所上市的美国上市公司），担任首席财务官，此前在公共会计领域有超过20年的经验，主要服务于制药行业。他于2018年从West PharmaceuticalServices，Inc.退休。他已于2021年5月被任命为Stevanato Group的董事会成员。
- William Federici,Holding a BA in Economics from Rutgers University, Livingston College and an MBA in Professional Accounting from Rutgers University, he is a member of the American Institute of Certified Public Accountants. Mr. Federici has been a member of the board of directors of Zynerba Pharmaceuticals, Inc., a Specialty Pharmaceutical, U.S. public company, where he has served as Audit Committee Board Chair since 2015. Mr. Federici joined West Pharmaceutical Services, Inc., a NYSE traded U.S. public company, in 2003 as Chief Financial Officer after more than 20 years’ experience in public accounting primarily serving the Pharmaceutical Industry. He retired from West Pharmaceutical Services, Inc. in 2018. He has been appointed as member of the board of directors of Stevanato Group in May 2021.
- Paola Vezzaro
-
Paola Vezzaro，1993年毕业于米兰商业大学Luigi Bocconi工商管理专业，成绩优异，随后毕业于米兰大学政治学和社会学专业。她还获得了米兰卡托利卡大学的人力资源硕士学位。Vezzaro女士在人力资源领域有着丰富的经验，曾在许多主要公司担任人力资源总监。她于2011年加入Engie，在那里她曾担任多个备受瞩目的国际人力资源职位。自2019年7月以来，她一直担任Engie的北欧、南欧和东欧首席人力资源和健康安全官。她已于2021年5月被任命为Stevanato Group的董事会成员。
Paola Vezzaro,Graduated, summa cum laude, in Business Administration from the University Commerciale “Luigi Bocconi” in Milan in 1993 and, subsequently, graduated in Political Science and Sociology from the University of Milan. She also obtained a Master in Human Resources from Cattolica University in Milan. Mrs. Vezzaro has an extensive experience in the HR fields, having served as HR director in many primary companies. She joined Engie in 2011 where she has held several HR high-profile international positions. Since July 2019 she has been serving as Chief Human Resources and Health & Safety Officer North, South and Eastern Europe for Engie. She has been appointed as member of the board of directors of Stevanato Group in May 2021. - Paola Vezzaro，1993年毕业于米兰商业大学Luigi Bocconi工商管理专业，成绩优异，随后毕业于米兰大学政治学和社会学专业。她还获得了米兰卡托利卡大学的人力资源硕士学位。Vezzaro女士在人力资源领域有着丰富的经验，曾在许多主要公司担任人力资源总监。她于2011年加入Engie，在那里她曾担任多个备受瞩目的国际人力资源职位。自2019年7月以来，她一直担任Engie的北欧、南欧和东欧首席人力资源和健康安全官。她已于2021年5月被任命为Stevanato Group的董事会成员。
- Paola Vezzaro,Graduated, summa cum laude, in Business Administration from the University Commerciale “Luigi Bocconi” in Milan in 1993 and, subsequently, graduated in Political Science and Sociology from the University of Milan. She also obtained a Master in Human Resources from Cattolica University in Milan. Mrs. Vezzaro has an extensive experience in the HR fields, having served as HR director in many primary companies. She joined Engie in 2011 where she has held several HR high-profile international positions. Since July 2019 she has been serving as Chief Human Resources and Health & Safety Officer North, South and Eastern Europe for Engie. She has been appointed as member of the board of directors of Stevanato Group in May 2021.
- Franco Moro
-
Franco Moro，1987年毕业于帕多瓦大学化学工程系，获得米兰SDA Bocconi工商管理硕士学位。Moro先生拥有超过30年的管理全球制造公司的丰富经验。他曾担任FIS-Fabbrica Italiana Sintetici和Cambrex Profarmaco Milano的工厂总监，之后从2010年到2018年担任FIS-Fabbrica Italiana Sintetici的首席执行官。Moro先生于2019年加入Stevanato Group，在担任首席运营官2年后，于2021年2月被任命为首席执行官。他自2021年2月被任命为Stevanato Group的董事会成员。
Franco Moro,Graduated in Chemical Engineering from the University of Padua in 1987 he obtained an MBA from SDA Bocconi in Milan. Mr. Moro has gained significant experience managing global manufacturing companies for over 30 years. He has worked as plant director of FIS-Fabbrica Italiana Sintetici and then of Cambrex Profarmaco Milano, before taking over as Chief Executive Officer of FIS-Fabbrica Italiana Sintetici from 2010 to 2018. Mr. Moro joined Stevanato Group in 2019 and after serving as Chief Operating Officer for 2 years, was appointed as Chief Executive Officer in February 2021. He has been appointed as member of the board of directors of Stevanato Group since February 2021. - Franco Moro，1987年毕业于帕多瓦大学化学工程系，获得米兰SDA Bocconi工商管理硕士学位。Moro先生拥有超过30年的管理全球制造公司的丰富经验。他曾担任FIS-Fabbrica Italiana Sintetici和Cambrex Profarmaco Milano的工厂总监，之后从2010年到2018年担任FIS-Fabbrica Italiana Sintetici的首席执行官。Moro先生于2019年加入Stevanato Group，在担任首席运营官2年后，于2021年2月被任命为首席执行官。他自2021年2月被任命为Stevanato Group的董事会成员。
- Franco Moro,Graduated in Chemical Engineering from the University of Padua in 1987 he obtained an MBA from SDA Bocconi in Milan. Mr. Moro has gained significant experience managing global manufacturing companies for over 30 years. He has worked as plant director of FIS-Fabbrica Italiana Sintetici and then of Cambrex Profarmaco Milano, before taking over as Chief Executive Officer of FIS-Fabbrica Italiana Sintetici from 2010 to 2018. Mr. Moro joined Stevanato Group in 2019 and after serving as Chief Operating Officer for 2 years, was appointed as Chief Executive Officer in February 2021. He has been appointed as member of the board of directors of Stevanato Group since February 2021.
- Fabrizio Bonanni
-
Fabrizio Bonanni，持有化学博士学位，优等生，荣誉奖，来自意大利佛罗伦萨大学，Bonanni先生在麻省理工学院进行了生理化学博士后工作。他是国际管理研究所的校友，西北大学，J.L.凯洛格管理研究生院，以及哈佛大学制造研究所工商管理研究生院的执行计划。他在意大利、比利时和美国的巴克斯特国际公司（Baxter International）工作了25年，先后担任公司质量体系副总裁、CVP监管和临床事务副总裁。1999年至2013年，他在安进担任高级行政职务，包括高级副总裁、质量与合规部和企业合规官、高级副总裁、制造部和运营部执行副总裁。目前，他是INCOG BioPharma Services董事会成员，UCLA技术开发公司董事，加州圣何塞InCube实验室顾问委员会成员。他过去的董事会成员包括XBiotech（他担任审计委员会主席）、Menarini Biotech和Theranos（他担任合规和质量委员会主席）。他自2013年起担任Stevanato集团董事会成员。
Fabrizio Bonanni,Holding a doctorate in chemistry, summa cum laude, mention of honor, from the University of Florence, Italy, Mr. Bonanni carried out postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration. He spent 25 years at Baxter International in Italy, Belgium and the U.S. reaching the positions of corporate vice president Quality System and CVP Regulatory and Clinical Affairs. From 1999 to 2013 he served in senior executive roles at Amgen, including senior vice president, Quality and Compliance and corporate compliance officer, senior vice president, Manufacturing and executive vice president, Operations. Currently, he is a member of the board of INCOG BioPharma Services, a director of UCLA's Technology Development Corporation and serves on the Advisory Board of InCube Labs of San Jose, California. His past board memberships include XBiotech, where he chaired the Audit Committee, Menarini Biotech, and Theranos, where he chaired the Compliance and Quality Committee. He has been a member of the board of directors of Stevanato Group since 2013. - Fabrizio Bonanni，持有化学博士学位，优等生，荣誉奖，来自意大利佛罗伦萨大学，Bonanni先生在麻省理工学院进行了生理化学博士后工作。他是国际管理研究所的校友，西北大学，J.L.凯洛格管理研究生院，以及哈佛大学制造研究所工商管理研究生院的执行计划。他在意大利、比利时和美国的巴克斯特国际公司（Baxter International）工作了25年，先后担任公司质量体系副总裁、CVP监管和临床事务副总裁。1999年至2013年，他在安进担任高级行政职务，包括高级副总裁、质量与合规部和企业合规官、高级副总裁、制造部和运营部执行副总裁。目前，他是INCOG BioPharma Services董事会成员，UCLA技术开发公司董事，加州圣何塞InCube实验室顾问委员会成员。他过去的董事会成员包括XBiotech（他担任审计委员会主席）、Menarini Biotech和Theranos（他担任合规和质量委员会主席）。他自2013年起担任Stevanato集团董事会成员。
- Fabrizio Bonanni,Holding a doctorate in chemistry, summa cum laude, mention of honor, from the University of Florence, Italy, Mr. Bonanni carried out postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration. He spent 25 years at Baxter International in Italy, Belgium and the U.S. reaching the positions of corporate vice president Quality System and CVP Regulatory and Clinical Affairs. From 1999 to 2013 he served in senior executive roles at Amgen, including senior vice president, Quality and Compliance and corporate compliance officer, senior vice president, Manufacturing and executive vice president, Operations. Currently, he is a member of the board of INCOG BioPharma Services, a director of UCLA's Technology Development Corporation and serves on the Advisory Board of InCube Labs of San Jose, California. His past board memberships include XBiotech, where he chaired the Audit Committee, Menarini Biotech, and Theranos, where he chaired the Compliance and Quality Committee. He has been a member of the board of directors of Stevanato Group since 2013.
高管简历
中英对照 | 中文 | 英文- Franco Moro
Franco Moro，1987年毕业于帕多瓦大学化学工程系，获得米兰SDA Bocconi工商管理硕士学位。Moro先生拥有超过30年的管理全球制造公司的丰富经验。他曾担任FIS-Fabbrica Italiana Sintetici和Cambrex Profarmaco Milano的工厂总监，之后从2010年到2018年担任FIS-Fabbrica Italiana Sintetici的首席执行官。Moro先生于2019年加入Stevanato Group，在担任首席运营官2年后，于2021年2月被任命为首席执行官。他自2021年2月被任命为Stevanato Group的董事会成员。
Franco Moro,Graduated in Chemical Engineering from the University of Padua in 1987 he obtained an MBA from SDA Bocconi in Milan. Mr. Moro has gained significant experience managing global manufacturing companies for over 30 years. He has worked as plant director of FIS-Fabbrica Italiana Sintetici and then of Cambrex Profarmaco Milano, before taking over as Chief Executive Officer of FIS-Fabbrica Italiana Sintetici from 2010 to 2018. Mr. Moro joined Stevanato Group in 2019 and after serving as Chief Operating Officer for 2 years, was appointed as Chief Executive Officer in February 2021. He has been appointed as member of the board of directors of Stevanato Group since February 2021.- Franco Moro，1987年毕业于帕多瓦大学化学工程系，获得米兰SDA Bocconi工商管理硕士学位。Moro先生拥有超过30年的管理全球制造公司的丰富经验。他曾担任FIS-Fabbrica Italiana Sintetici和Cambrex Profarmaco Milano的工厂总监，之后从2010年到2018年担任FIS-Fabbrica Italiana Sintetici的首席执行官。Moro先生于2019年加入Stevanato Group，在担任首席运营官2年后，于2021年2月被任命为首席执行官。他自2021年2月被任命为Stevanato Group的董事会成员。
- Franco Moro,Graduated in Chemical Engineering from the University of Padua in 1987 he obtained an MBA from SDA Bocconi in Milan. Mr. Moro has gained significant experience managing global manufacturing companies for over 30 years. He has worked as plant director of FIS-Fabbrica Italiana Sintetici and then of Cambrex Profarmaco Milano, before taking over as Chief Executive Officer of FIS-Fabbrica Italiana Sintetici from 2010 to 2018. Mr. Moro joined Stevanato Group in 2019 and after serving as Chief Operating Officer for 2 years, was appointed as Chief Executive Officer in February 2021. He has been appointed as member of the board of directors of Stevanato Group since February 2021.
- Marco Dal Lago
Marco Dal Lago，1997年毕业于威尼斯福斯卡里大学，获得工商管理学位。Dal Lago先生于2020年1月加入Stevanato Group，此前在控制、金融、行政、合规和风险管理领域拥有约25年的经验，在跨国工业公司工作，并协调多年规划和并购流程。Dal Lago先生目前是Stevanato Group的首席财务官，负责集团管理、财务和控制活动的组织、监督和担保。
Marco Dal Lago,Graduated from Ca’ Foscari University of Venice in 1997 with a degree in Business Administration. Mr. Dal Lago joined Stevanato Group in January 2020 after about 25 years of experience in the fields of controlling, finance, administration, compliance and risk management, working in multinational industrial companies and coordinating multi-year planning and mergers & acquisitions processes. Mr. Dal Lago is currently Chief Financial Officer at Stevanato Group, with responsibility for the organization, supervision and guarantee of Group administration, finance and controlling activities.- Marco Dal Lago，1997年毕业于威尼斯福斯卡里大学，获得工商管理学位。Dal Lago先生于2020年1月加入Stevanato Group，此前在控制、金融、行政、合规和风险管理领域拥有约25年的经验，在跨国工业公司工作，并协调多年规划和并购流程。Dal Lago先生目前是Stevanato Group的首席财务官，负责集团管理、财务和控制活动的组织、监督和担保。
- Marco Dal Lago,Graduated from Ca’ Foscari University of Venice in 1997 with a degree in Business Administration. Mr. Dal Lago joined Stevanato Group in January 2020 after about 25 years of experience in the fields of controlling, finance, administration, compliance and risk management, working in multinational industrial companies and coordinating multi-year planning and mergers & acquisitions processes. Mr. Dal Lago is currently Chief Financial Officer at Stevanato Group, with responsibility for the organization, supervision and guarantee of Group administration, finance and controlling activities.
- Mauro Stocchi
Mauro Stocchi，1991年毕业于威尼斯福斯卡利大学，拥有米兰SDA Bocconi工商管理硕士学位。斯托奇的职业生涯始于德隆吉股份公司（de Longhi S.p.A.），之后在西门子集团任职10年。他于2004年加入Stevanato Group，并于2008年被任命为集团首席财务官，同时继续负责业务发展活动。从2010年起，他担任公司总经理，直接负责所有公司职能。他还担任制药系统部门的总经理，目前是集团的首席商务官，负责战略业务开发、销售、产品管理、营销和沟通以及药物输送系统业务。
Mauro Stocchi,Graduated from Ca’ Foscari University of Venice in 1991 and holds a Masters of Business Administration from SDA Bocconi in Milan. Mr. Stocchi commenced his career in De Longhi S.p.A. followed by a 10-year period within the Siemens Group. He joined Stevanato Group in 2004 and in 2008 Mr. Stocchi was appointed CFO of the Group while retaining responsibility over business development activities. From 2010 he covered the position of Corporate General Manager with direct responsibility for all corporate functions. He also served as General Manager of the Pharmaceutical System Division and is currently Chief Business Officer of the Group with responsibilities of strategic business development, sales, product management, marketing and communication and drug delivery systems business.- Mauro Stocchi，1991年毕业于威尼斯福斯卡利大学，拥有米兰SDA Bocconi工商管理硕士学位。斯托奇的职业生涯始于德隆吉股份公司（de Longhi S.p.A.），之后在西门子集团任职10年。他于2004年加入Stevanato Group，并于2008年被任命为集团首席财务官，同时继续负责业务发展活动。从2010年起，他担任公司总经理，直接负责所有公司职能。他还担任制药系统部门的总经理，目前是集团的首席商务官，负责战略业务开发、销售、产品管理、营销和沟通以及药物输送系统业务。
- Mauro Stocchi,Graduated from Ca’ Foscari University of Venice in 1991 and holds a Masters of Business Administration from SDA Bocconi in Milan. Mr. Stocchi commenced his career in De Longhi S.p.A. followed by a 10-year period within the Siemens Group. He joined Stevanato Group in 2004 and in 2008 Mr. Stocchi was appointed CFO of the Group while retaining responsibility over business development activities. From 2010 he covered the position of Corporate General Manager with direct responsibility for all corporate functions. He also served as General Manager of the Pharmaceutical System Division and is currently Chief Business Officer of the Group with responsibilities of strategic business development, sales, product management, marketing and communication and drug delivery systems business.
- Paolo Patri
Paolo Patri，1995年毕业于米兰大学，获化学学位。Patri先生在制药行业拥有超过20年的经验，包括在制药和生物技术的生产和开发方面，在通过标准和加速程序实现大、小分子和组合药物产品的全球监管批准方面取得了重要的记录。Patri先生在不同的国际组织担任过各种职务，包括Cambrex Profarmaco，Janseen-Cilag A强生公司Company，Chiesi Farmaceutici and Dompé；Farmaceutici。在Chiesi Farmaceutici，他从2008年到2017年担任CMC化学、制造和控制全球主管。在Dompé；Farmaceutici，他担任首席制造官。Patri先生于2018年10月加入Stevanato Group，此后担任首席技术官，监督研究与开发部门的管理，以及支持集团愿景的投资、项目和其他活动。
Paolo Patri,Graduated from the University of Milan in 1995 with a degree in Chemistry. Mr. Patri has over 20 years of experience in the pharmaceutical industry, both in production and in the development of pharmaceuticals and biotech, gaining a significant track record of achieving global regulatory approvals for both large, small molecules and combination medicinal product through standard and accelerated programs. Mr. Patri held various positions at different international organizations, including Cambrex Profarmaco, Janseen-Cilag a Johnson & Johnson company, Chiesi Farmaceutici and Dompé Farmaceutici. In Chiesi Farmaceutici he held from 2008 to 2017 the role of Global Head of CMC Chemistry, Manufacturing and Controls. In Dompé Farmaceutici, he held the role of Chief Manufacturing Officer. Mr. Patri joined Stevanato Group in October 2018 and has since assumed the role of Chief Technology Officer, overseeing the management of the research and development department, as well as investments, projects and other activities supporting the Group vision.- Paolo Patri，1995年毕业于米兰大学，获化学学位。Patri先生在制药行业拥有超过20年的经验，包括在制药和生物技术的生产和开发方面，在通过标准和加速程序实现大、小分子和组合药物产品的全球监管批准方面取得了重要的记录。Patri先生在不同的国际组织担任过各种职务，包括Cambrex Profarmaco，Janseen-Cilag A强生公司Company，Chiesi Farmaceutici and Dompé；Farmaceutici。在Chiesi Farmaceutici，他从2008年到2017年担任CMC化学、制造和控制全球主管。在Dompé；Farmaceutici，他担任首席制造官。Patri先生于2018年10月加入Stevanato Group，此后担任首席技术官，监督研究与开发部门的管理，以及支持集团愿景的投资、项目和其他活动。
- Paolo Patri,Graduated from the University of Milan in 1995 with a degree in Chemistry. Mr. Patri has over 20 years of experience in the pharmaceutical industry, both in production and in the development of pharmaceuticals and biotech, gaining a significant track record of achieving global regulatory approvals for both large, small molecules and combination medicinal product through standard and accelerated programs. Mr. Patri held various positions at different international organizations, including Cambrex Profarmaco, Janseen-Cilag a Johnson & Johnson company, Chiesi Farmaceutici and Dompé Farmaceutici. In Chiesi Farmaceutici he held from 2008 to 2017 the role of Global Head of CMC Chemistry, Manufacturing and Controls. In Dompé Farmaceutici, he held the role of Chief Manufacturing Officer. Mr. Patri joined Stevanato Group in October 2018 and has since assumed the role of Chief Technology Officer, overseeing the management of the research and development department, as well as investments, projects and other activities supporting the Group vision.